333 related articles for article (PubMed ID: 31477350)
1. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
[TBL] [Abstract][Full Text] [Related]
2. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Poratti M; Marzaro G
Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
[TBL] [Abstract][Full Text] [Related]
3. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
6. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
7. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
8. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
9. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
10. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
11. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
12. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
14. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
Lynce F; Shajahan-Haq AN; Swain SM
Pharmacol Ther; 2018 Nov; 191():65-73. PubMed ID: 29933034
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
17. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
20. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
